论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
带有 ETV6::PDGFRB 融合基因的髓系/淋巴肿瘤:伊马替尼反应不佳的罕见病例以及从骨髓髓系肿瘤向淋巴结T细胞淋巴母细胞淋巴瘤侵袭的可能转化机制
Authors Gou Y, Tang Y, Liu S, Cheng S, Deng X, Wen Q, Feng Y, Peng X, Wang P, Zhang X
Received 24 July 2023
Accepted for publication 20 September 2023
Published 11 November 2023 Volume 2023:16 Pages 5163—5170
DOI https://doi.org/10.2147/JIR.S427995
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Abstract: The ETV6::PDGFRB fusion gene is commonly reported in chronic myelomonocytic leukemia with eosinophilia, yet patients with ETV6::PDGFRB presenting myeloid and lymphoid neoplasms successively have not been reported. Here, we report the first case of a 35-year-old man with myeloid and lymphoid neoplasms harboring an ETV6::PDGFRB fusion gene who demonstrated poor response to imatinib. The patient was diagnosed with an ETV6::PDGFRB fusion gene myeloid neoplasm on initial diagnosis at our hospital. After 5 months of treatment with imatinib, he was diagnosed with T-cell lymphoblastic lymphoma. ETV6::PDGFRB turned negative after increasing the dose of imatinib, but enlarged superficial lymph nodes reappeared the following year. Notably, the patient exhibited a worse response to imatinib treatment. This study describes this rare case and speculates on a possible mechanism.
Keywords: ETV6, PDGFRB , fusion, myeloid/lymphoid neoplasms, imatinib